The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics (VKTX) stock plunges and short sellers betting against the company gain $521M amid the selloff. Read more here.

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

After Viking Therapeutics (VKTX) yesterday announced 13-week Phase 2 data for VK2735, an oral GIP/GLP-1-based candidate for obesity, Mizuho notes ...

Unusual total active option classes on open include: Stratasys ( SSYS ), Hertz Global Holdings ( HTZ ), Estee Lauder ( EL ), Lowe’s ( LOW ), Annaly Capital ( NLY ), Viking Therapeutics ( VKTX ), Baidu ...

Shares of Viking Therapeutics, Inc. (VKTX) experienced a dramatic sell-off, collapsing 42% following the release of new data for its weight-loss drug candidate, VK2735. The sharp decline reflects a ...

Nasdaq futures dipped a further 0.4% after investors sold AI tech stocks yesterday, leading to a near-1.5% daily decline, though the index is still up 40% since April's low. Palantir ( PLTR -9.39%) ...

Wednesday’s market has seen notable swings among various stocks, with significant movements particularly in the mega-cap and large-cap categories. As the trading day unfolds, companies like Tesla ...

Why did Viking Therapeutics stock drop after its obesity drug trial update? Viking Therapeutics shares slumped sharply this week after the company’s latest obesity drug trial update failed to match ...